Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Abstract Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antig...

Full description

Bibliographic Details
Main Authors: Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia
Format: Article
Language:English
Published: BMJ Publishing Group 2018-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1 inhibitor
PD-L1 inhibitor
Clinical trials
Biomarkers
Immune checkpoint
Hyperprogressors
Online Access:http://link.springer.com/article/10.1186/s40425-018-0316-z

Internet

http://link.springer.com/article/10.1186/s40425-018-0316-z

Similar Items